Out Now: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
Following its recent announcement, the AmoyDx® FGFR1-4 NGS Panel (RUO) is now available offering a robust NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in FGFR1-4 genes at DNA and RNA levels, respectively. The panel covers the full coding sequences of all four genes and utilizes a hybrid capture technology (ddCAP) for library preparation. Its optimized DNA/cDNA co-library preparation workflow mostly takes place within a single reaction tube, enhancing efficiency and ease of use.
Learn more here.
For further information, please contact us at molpath@zytomed-systems.de
Further topics
News about the IVDR
The IVDR, in force since May 26, 2022, represents a turning point in the EU-wide harmonization of patient safety. At the same time, it places high demands on us as manufacturers and on you as a user of in vitro diagnostic medical devices to implement the new regulation. We would like to meet this challenge together with you for the benefit of your patients. It is important to us to certify our portfolio of diagnostic solutions in compliance with the IVDR in due time. Therefore, we would like to keep you informed about our progress with the implementation of the IVDR.
Product update: BRCA1 and BRCA2
The new AmoyDx® BRCA Pro Panel is an improved version of the AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit. Both kits enable analysis of the entire coding regions of the BRCA1 and BRCA2 genes, and of exon/ intron boundries in DNA from FFPE specimen and from peripheral whole blood.
